Small pancreatic tubular adenocarcinomas: Clinicopathological analysis with immunohistochemical and histochemical evaluation

Pathology International

Volumn 46, Issue 8, 1996, Pages 581-588

  Matsukuma, Susumu ^a,b,c   Suda, Koichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Department of Pathology   (Japan)

^c Self Defense Forces Central Hospital   (Japan)

Author keywords

adenocarcinoma; c erbB 2; clinicopathological study; galactose oxidase cold thionine Schiff paradoxical concanavalin A staining; p53; small pancreatic cancer

Indexed keywords

PROTEIN P53; STOMACH MUCIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE C ERB; ONCOGENE H RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

EID: 0029836301     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1996.tb03657.x     Document Type: Article

References (29)

1. Matsuno S, Sato T. Surgical treatment for carcinoma of the pancreas. Am. J. Surg. 1986; 152: 499-504.
2. Carriaga MT, Henson DE. Liver, gall-bladder, extrahepatic bile ducts and pancreas. Cancer 1995; 75: 171-190.
3. Tsuchiya R, Tomioka T, Izawa K et al. Collective review of small carcinomas of the pancreas. Ann. Surg. 1986; 203: 77-81.
4. Manabe T, Miyashita T, Ohshio G et al. Small carcinoma of the pancreas: Clinical and pathologic evaluation of 17 patients. Cancer 1988; 62: 135-144.
5. Satake K, Nishiwaki H, Yokomatsu H et al. Surgical curability and progress for standard versus extended resection for T1 carcinoma of the pancreas. Surg. Gynecol. Obstet. 1992; 175: 259-265.
6. Furukawa T, Takahashi T, Kobari M, Matsuno S. The mucus-hypersecreting tumor of the pancreas. Cancer 1992; 70: 1505-1513.
7. Japanese Pancreatic Society. General Rules for the Study of Pancreatic Cancer, 4th edn. Kanehara Publishing, Tokyo, 1993 (in Japanese).
8. Ota H, Katsuyama T, Ishii K, Nakayama J, Shiozawa T, Tsukahara Y. A dual staining method for identifying mucin of different gastric epithelial mucous cells. Histochem. J. 1991; 23: 22-28.
9. Culling CFA, Reid PE, Worth AW. Carbohydrate markers in the lower gastro-intestinal tract. Methods Achiev. Exp. Pathol. 1981; 10: 73-100.
10. Japanese Pancreatic Society. General Rules for Surgical and Pathological Studies on Cancer of the Pancreas, 2nd edn. Kanehara Publishing, Tokyo, 1982 (in Japanese).
11. Japanese Pancreatic Society. General Rules for Surgical and Pathological Studies on Cancer of the Pancreas, 3rd edn. Kanehara Publishing, Tokyo, 1986 (in Japanese).
12. Zhang SY, Ruggeri B, Agarwal P et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch. Pathol. Lab. Med. 1994; 118: 150-154.
13. Suzuki T, Takano Y. Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions in pancreatic duct cell carcinomas. Jpn. J. Cancer Res. 1993; 84: 1072-1077.
14. DiGiuseppe JA, Hruban RH, Goodman SN et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol. 1994; 101: 684-688.
15. Scarpa A, Capelli P, Mukai K et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am. J. Pathol. 1993; 142: 1534-1543.
16. Yamaguchi K, Enjoji M. Carcinoma of the pancreas: A conclusive study of 96 cases with immunohistochemical observation. Jpn. J. Clin. Oncol. 1989; 19: 14-22.
17. Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign and malignant human pancreatic tissues. Hum. Pathol. 1990; 21: 607-612.
18. Hall Pa, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemione NR. The c-erbB-2 proto-oncogene in human pancreatic cancer. J. Pathol. 1990; 161: 195-200.
19. Uchida E, Onda M, Yamanaka Y et al. Immunohistochemical expressions of myc and c-erbB-2 oncogene products in human pancreatic cancer. Tann To Sui 1991; 13: 269-273 (in Japanese).
20. Satoh K, Sasano H, Shimosegawa T et al. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. Cancer 1993; 72: 51-56.
21. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis. Hum. Pathol. 1993; 24: 469-476.
22. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int. J. Cancer 1992; 50: 859-862.
23. Chen J, Baitnun SI, Ramsay MA. Histogenesis of pancreatic carcinomas: A study based on 248 cases. J. Pathol. 1985; 146: 65-76.
24. Sommers SC, Murphy SA, Warren S. Pancreatic duct hyperplasia and cancer. Gastroenterology 1954; 27: 629-640.
25. Kozuka S, Sassa R, Taki T et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979; 43: 1418-1428.
26. Yanagisawa A, Ohtake K, Ohashi K et al. C-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res. 1993; 53: 953-956.
27. Matsuzawa K, Akamatsu T, Katsuyama T. Mucin histochemistry of pancreatic duct cell carcinoma, with special reference to organoid differentiation simulating gastric pyloric mucosa. Hum. Pathol. 1992; 23: 925-933.
28. Cubilla AL, Fitzgerald PJ. Tumors of the exocrine pancreas. In: Hartmann WH, ed. Atlas of Tumor Pathology, fascicle 19, 2nd series. Armed Forces Institute of Pathology, Washington, DC, 1984; 71-89, 144-146.
29. Pour PM, Sayed S, Sayed G. Hyperplastic, preneoplastic, and neoplastic lesions found in 83 human pancreases. Am. J. Clin. Pathol. 1982; 77: 137-152.